Skip to main content
    C

    Compass Therapeutics Inc. (CMPX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.66
    -0.11 (-14.51%)

    Market Cap: $139.35M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Compass Therapeutics Inc. (CMPX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Compass Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was -$66.49M, operating cash flow was -$49.14M and free cash flow was -$49.17M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$27.17M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $72.84M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0-100.0%N/AN/AN/A
    Dec 2024$850.00KN/A100.0%-6661.8%-5808.8%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$0$850.00K$0$0$0$0$0$0
    Cost of revenue$0$0$0$0$0$0$0$1.92M
    Gross profit$0$850.00K$0$0$0$0$0-$1.92M
    Research and development$55.97M$42.34M$38.12M$30.00M$70.95M$14.90M$22.45M$27.09M
    Operating income-$72.84M-$56.63M-$50.36M-$41.66M-$81.88M-$27.81M-$34.05M-$38.31M
    Net income-$66.49M-$49.38M-$42.49M-$39.23M-$82.18M-$29.50M-$34.74M-$38.29M
    EBITDA-$66.69M-$49.27M-$43.83M-$38.12M-$80.56M-$27.06M-$31.30M-$35.73M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$0$0$850.00K$0$2.84M
    Gross profit$0$0$0-$370.00K$0$0$0N/A$0$850.00K$0$2.38M
    Operating income-$28.80M-$26.98M-$20.30M-$17.99M-$15.82M-$21.07M-$17.97M-$16.57M-$12.24M-$15.04M-$12.77M-$15.39M
    Net income-$27.17M-$25.15M-$18.32M-$15.72M-$14.26M-$19.88M-$16.63M-$15.03M-$10.48M-$13.08M-$10.79M-$13.41M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.00M by $29.64M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Mar 2019Dec 2018Mar 2018
    Total assets$219.59M$140.40M$156.88M$199.65M$153.76M$51.91M$4.87K$4.87K$25$25
    Current assets$209.82M$132.75M$153.88M$194.79M$147.10M$50.20M$4.87K$4.87K$25$25
    Cash and equivalents$30.64M$43.48M$24.23M$34.95M$144.51M$47.08M$4.87K$4.87K$0$0
    Total liabilities$22.80M$15.17M$8.34M$18.01M$13.68M$11.97M$75.45K$75.45K$34.58K$34.58K
    Short-term debt$1.00M$338.00K$1.20M$1.10M$989.00K$7.47M$72.13K$72.13K$34.52K$34.52K
    Long-term debtN/AN/AN/AN/AN/A$1.87M$9.29MN/A$11.06MN/A
    Shareholder equity$196.79M$125.23M$148.54M$181.64M$140.08M$39.95M-$70.59K-$70.59K-$34.55K-$34.55K
    Fiscal years ended Mar 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$174.50M$190.17M$205.17M$219.59M$231.26M$116.70M$131.45M$140.40M$149.15M$155.61M$161.14M$156.88M
    Total liabilities$31.93M$24.12M$18.70M$22.80M$21.65M$23.49M$21.17M$15.17M$10.75M$9.51M$4.08M$8.34M
    Cash and equivalents$41.47M$35.45M$55.17M$30.64M$46.21M$22.86M$41.05M$43.48M$36.80M$19.40M$23.67M$24.23M
    Shareholder equity$142.57M$166.05M$186.47M$196.79M$209.61M$93.21M$110.28M$125.23M$138.40M$146.10M$157.06M$148.54M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$49.14M-$44.85M-$40.62M-$34.13M-$19.67M-$26.80M-$31.74M-$33.68M
    Capital expenditures$25.00K$44.00K$30.00K$212.00K$1.57M$106.00K$466.00K$2.02M
    Free cash flow-$49.17M-$44.90M-$40.65M-$34.34M-$21.23M-$26.91M-$32.21M-$35.70M
    Share repurchases$8.64M$543.00K$94.00K$495.00K$281.00K$6.32M$0N/A
    Investing cash flow-$93.31M$46.77M$26.96M-$151.20M-$1.77M$38.00K-$466.00K-$2.02M
    Financing cash flow$129.61M$17.34M$2.94M$75.76M$118.61M$48.54M$0$64.03M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$16.32M-$14.74M-$17.27M-$13.25M-$10.85M-$11.83M-$13.21M-$9.16M-$11.05M-$10.75M-$13.89M-$12.35M
    Capital expenditures$106.00K$176.00K$82.00K$0$7.00K$0$18.00K$0$44.00K$0$0$9.00K
    Free cash flow-$16.42M-$14.91M-$17.35M-$13.25M-$10.86M-$11.83M-$13.23M-$9.16M-$11.10M-$10.75M-$13.89M-$12.36M
    Last 12 quarters

    Frequently Asked Questions About CMPX

    What is Compass Therapeutics' annual revenue?

    Compass Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    How fast is Compass Therapeutics' revenue growing?

    Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Compass Therapeutics profitable?

    No. Compass Therapeutics reported net income of -$66.49M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does CMPX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$49.14M minus capital expenditures of $25.00K produced free cash flow of -$49.17M.

    How much debt does Compass Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.00M and cash and equivalents of $30.64M.